5 Key Sessions, Interviews at 65th American Society of Hematology Annual Meeting

This year’s ASH Meeting could be one of the largest in its history, with an expected record number of abstracts, according to 2023 ASH president Robert A. Brodsky, MD, in an interview with Pharmacy Times. At ASH, the program is set to include late-breaking sessions and abstracts, oral and poster presentations, updates on industry trends in hematology and oncology, scientific and educational programs with feature panel discussions and Q & As, and much more. Experts will discuss new diagnostic tools, therapies, and clinical trials that are set to change the treatment landscape as we know it.

Image credit: Saiful52 | stock.adobe.com

Pharmacy Times will also feature exclusive interviews with presenters.

Stay tuned on PharmacyTimes.com for session coverage and interviews, which include:

• A session that will discuss the results of a multi-cohort study that evaluated the efficacy of a novel artificial intelligence (AI) to distinguish between prefibrotic primary myelofibrosis (prePMF) and essential thrombocythemia (ET); this may help clinicians to identify the most beneficial therapies for patients depending on the disease.
• An interview with Xiaolin Zhang, PhD, the founder, chairman and CEO of Dizal Pharmaceuticals, who will discuss positive results from a pivotal trial evaluating the Janus kinase 1 inhibitor goldicitinib for aggressive peripheral T-cell lymphoma. Zhang will also discuss preclinical data on a new drug for refractory or relapsed B-Cell Non-Hodgkin Lymphoma.
• A session presented by Julie Kanter, MD, on Monday December 11, which will discuss 5-year follow-up data on the efficacy, safety, and health-related quality of life associated with lovotibeglogene autotemcel (Lovo-cel) gene therapy for patients with sickle cell disease.
• A conversation with Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, a clinical pharmacy manager of hematology, bone marrow therapy, and cellular therapeutics with the University of Kansas Health System, who will be breaking down results from the GLAMM1 Study and provide in-depth discussion about the barriers to chimeric antigen receptor (CART) therapy and other novel targeted treatments.
• A presentation that will discuss the results of the phase 3 FLAIR study, which compared ibrutinib and venetoclax with chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia. Highlights include significant positive efficacy data related to survival outcomes, and this combination could potentially serve as a new standard treatment option.

Stay tuned on PharmacyTimes.com and on our social media channels for all of these and more from the 65th ASH Annual Meeting.